ES2279884T3 - Tratamiento de la inflamacion articular cronica usando un anticuerpo contra el complejo por antigeno cd3. - Google Patents

Tratamiento de la inflamacion articular cronica usando un anticuerpo contra el complejo por antigeno cd3. Download PDF

Info

Publication number
ES2279884T3
ES2279884T3 ES02765050T ES02765050T ES2279884T3 ES 2279884 T3 ES2279884 T3 ES 2279884T3 ES 02765050 T ES02765050 T ES 02765050T ES 02765050 T ES02765050 T ES 02765050T ES 2279884 T3 ES2279884 T3 ES 2279884T3
Authority
ES
Spain
Prior art keywords
antibody
baselineskip
accordance
aglycosylated
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02765050T
Other languages
English (en)
Spanish (es)
Inventor
John Medical School Isaacs
Herman Waldmann
Geoffrey Therapeutic Antibody Centre Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9922741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2279884(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Application granted granted Critical
Publication of ES2279884T3 publication Critical patent/ES2279884T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES02765050T 2001-09-26 2002-09-26 Tratamiento de la inflamacion articular cronica usando un anticuerpo contra el complejo por antigeno cd3. Expired - Lifetime ES2279884T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0123156A GB2380127A (en) 2001-09-26 2001-09-26 Treatment of chronic joint inflammation
GB0123156 2001-09-26

Publications (1)

Publication Number Publication Date
ES2279884T3 true ES2279884T3 (es) 2007-09-01

Family

ID=9922741

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02765050T Expired - Lifetime ES2279884T3 (es) 2001-09-26 2002-09-26 Tratamiento de la inflamacion articular cronica usando un anticuerpo contra el complejo por antigeno cd3.
ES07000627T Expired - Lifetime ES2389781T3 (es) 2001-09-26 2002-09-26 Tratamiento de la inflamación articular crónica mediante un anticuerpo aglicosilado anti-CD3

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07000627T Expired - Lifetime ES2389781T3 (es) 2001-09-26 2002-09-26 Tratamiento de la inflamación articular crónica mediante un anticuerpo aglicosilado anti-CD3

Country Status (10)

Country Link
US (1) US20050037004A1 (enExample)
EP (3) EP2199307B1 (enExample)
JP (1) JP4694784B2 (enExample)
AU (2) AU2002329423B2 (enExample)
CA (1) CA2461714C (enExample)
DE (1) DE60217698T2 (enExample)
ES (2) ES2279884T3 (enExample)
GB (1) GB2380127A (enExample)
PT (1) PT1432445E (enExample)
WO (1) WO2003026692A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6660948B2 (en) * 2001-02-28 2003-12-09 Vip Investments Ltd. Switch matrix
CN102659946A (zh) 2002-03-13 2012-09-12 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
AU2004266159A1 (en) * 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
UA89780C2 (ru) * 2004-04-06 2010-03-10 Новиммюн С.А. Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела
AU2005250499B2 (en) 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
RU2271816C1 (ru) * 2004-07-08 2006-03-20 Григорий Менделевич Дубровин Способ профилактики посттравматического остеоартроза
EP1791563A4 (en) 2004-07-26 2009-07-08 Biogen Idec Inc ANTI-CD154 ANTIBODIES
US7740856B2 (en) 2005-12-20 2010-06-22 Isu Abxis Co., Ltd. Effect of BST2 on inflammation
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007117600A2 (en) * 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
JP2009542810A (ja) 2006-07-10 2009-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
EP2170951A2 (en) * 2007-05-31 2010-04-07 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
WO2010132872A1 (en) * 2009-05-15 2010-11-18 Novimmune S.A Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
WO2011050106A2 (en) * 2009-10-20 2011-04-28 Tolerx, Inc. Anti-cd3 antibody dosing in autoimmune disease
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
CN119095873A (zh) 2022-03-14 2024-12-06 拉姆卡普生物伽马股份公司 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
ATE174515T1 (de) 1991-10-15 1999-01-15 Btg Int Ltd Verwendung eines cdw52-spezifischen antikörpers zur behandlung von durch t-zellen vermittelten gelenkentzündungen
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
SE510197C2 (sv) 1997-02-06 1999-04-26 Asea Brown Boveri Förfarande och anordning för styrning av ett kondensatordon för en shuntkopplad statisk kompensatorenhet med deblockeringssignaler för indikering av icke strömförande tillstånd hos ingående ventiler
US5843597A (en) * 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
CA2224256C (en) 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AUPQ431299A0 (en) * 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance

Also Published As

Publication number Publication date
CA2461714A1 (en) 2003-04-03
GB2380127A (en) 2003-04-02
CA2461714C (en) 2013-03-12
EP1432445A2 (en) 2004-06-30
EP1803466A1 (en) 2007-07-04
EP2199307A1 (en) 2010-06-23
ES2389781T3 (es) 2012-10-31
JP2005506331A (ja) 2005-03-03
WO2003026692A2 (en) 2003-04-03
PT1432445E (pt) 2007-03-30
AU2008207338A1 (en) 2008-09-04
EP2199307B1 (en) 2014-11-05
AU2002329423B2 (en) 2008-05-15
DE60217698D1 (de) 2007-03-08
US20050037004A1 (en) 2005-02-17
GB0123156D0 (en) 2001-11-21
WO2003026692A3 (en) 2003-12-18
AU2008207338B2 (en) 2011-12-08
EP1803466B1 (en) 2012-07-11
EP1432445B1 (en) 2007-01-17
JP4694784B2 (ja) 2011-06-08
DE60217698T2 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
ES2279884T3 (es) Tratamiento de la inflamacion articular cronica usando un anticuerpo contra el complejo por antigeno cd3.
KR100491222B1 (ko) 사람치료를 위한 재조합 항-cd4 항체
US10329357B2 (en) Treatment of ocular disease
ES2341708T3 (es) Anticuerpos especificos de cd22 humana y sus usos terapeuticos y diagnosticos.
AU2002329423A1 (en) Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
JP2017515815A (ja) レナリドミド及びポリペプチド構築物の組合せ、及びその使用
CN118525035A (zh) 抗cldn18.2和4-1bb的双特异性抗原结合蛋白及其用途
HK40018434A (en) An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
NZ623275B2 (en) Treatment of ocular disease